Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study
- PMID: 15029512
- DOI: 10.1007/s10096-004-1103-y
Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study
Abstract
In order to update the epidemiological and mycological profile of candidaemia in Europe, the European Confederation of Medical Mycology conducted a prospective, sequential, hospital population-based study from September 1997 to December 1999. A total of 2,089 cases were documented by 106 institutions in seven European countries. Rates of candidaemia ranging from 0.20 to 0.38 per 1,000 admissions were reported. Candida albicans was identified in 56% of cases. Non-albicans Candida species were most frequently isolated from patients with haematological malignancies (65%). With increasing age, an increasing incidence of Candida glabrata was seen. The 30-day mortality rate was 37.9%. The survey results underline the burden of candidaemia in a wide range of patient populations, confirm the importance of non- albicans species, and provide baseline data for future surveillance studies at a European level.
Similar articles
-
Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):23-30. doi: 10.1007/s10096-004-1267-5. Eur J Clin Microbiol Infect Dis. 2005. PMID: 15619060
-
A prospective epidemiological survey of candidaemia in Sweden.Scand J Infect Dis. 2004;36(1):52-5. doi: 10.1080/00365540310017447. Scand J Infect Dis. 2004. PMID: 15000560
-
European Confederation of Medical Mycology (ECMM) prospective survey of candidaemia: report from one Italian region.J Hosp Infect. 2002 Aug;51(4):297-304. doi: 10.1053/jhin.2002.1261. J Hosp Infect. 2002. PMID: 12183145
-
Candidaemia in Europe: epidemiology and resistance.Int J Antimicrob Agents. 2006 May;27(5):359-66. doi: 10.1016/j.ijantimicag.2006.01.002. Epub 2006 Apr 27. Int J Antimicrob Agents. 2006. PMID: 16647248 Review.
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
Cited by
-
Mode of Action of a Designed Antimicrobial Peptide: High Potency against Cryptococcus neoformans.Biophys J. 2016 Oct 18;111(8):1724-1737. doi: 10.1016/j.bpj.2016.08.032. Biophys J. 2016. PMID: 27760359 Free PMC article.
-
Fungemia at a tertiary care hospital: incidence, therapy, and distribution and antifungal susceptibility of causative species.Eur J Clin Microbiol Infect Dis. 2007 Aug;26(8):541-7. doi: 10.1007/s10096-007-0339-8. Eur J Clin Microbiol Infect Dis. 2007. PMID: 17569999
-
Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling.J Clin Invest. 2007 Dec;117(12):3664-72. doi: 10.1172/JCI28115. J Clin Invest. 2007. PMID: 17992260 Free PMC article.
-
Invasive candidiasis and candidemia in pediatric and neonatal patients: A review of current guidelines.Curr Med Mycol. 2018 Sep;4(3):28-33. doi: 10.18502/cmm.4.3.173. Curr Med Mycol. 2018. PMID: 30619967 Free PMC article. Review.
-
Candida spp. co-infection in COVID-19 patients with severe pneumonia: Prevalence study and associated risk factors.Respir Med. 2021 Nov;188:106619. doi: 10.1016/j.rmed.2021.106619. Epub 2021 Sep 17. Respir Med. 2021. PMID: 34555702 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical